Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIA Study to Evaluate the Efficacy of HIF2a Inhibitor Belzutifan in Patients With Erythrocytosis by EPAS1 (HIF2a), EGLN1 (PHD2), or VHL Mutations

NCT07895966 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07895966 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIA Study to Evaluate the Efficacy of HIF2a Inhibitor Belzutifan in Patients With Erythrocytosis by EPAS1 (HIF2a), EGLN1 (PHD2), or VHL Mutations
Lead sponsor
University of Utah
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
September 30, 2028
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

erythrocytosis, pulmonary hypertension, thrombosis

Arms

As registered; 1 arm.

  • Belzutifan Treatment ExperimentalBelzutifan

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Normalization of hemoglobin 12 weeks

    Either normalizing Hb or lowering of patient Hb by at least 1.5g/dL from the patient's baseline by 12 weeks of therapy.

Lead sponsor's other trials

University of Utah, most recent start first.

Similar trials

Same condition (Polycythemia) and phase, most recent start first.